Last mentioned: Feb 27, 2026
Novartis Settlement
Novartis announces a confidential settlement with the Henrietta Lacks estate.
Ultragenyx Settlement
Ultragenyx settles with the estate over HeLa cell usage in gene therapy research.
Thermo Fisher Settlement
Thermo Fisher Scientific reaches a historic settlement with the Lacks family.
First Major Lawsuit
The Lacks estate files its first major lawsuit against Thermo Fisher Scientific.
Mass Production
HeLa cells are mass-produced and distributed globally, becoming a cornerstone of modern research.
Cells Harvested
Henrietta Lacks' cells are harvested without consent during cancer treatment at Johns Hopkins.
Novartis has reached a confidential settlement with the estate of Henrietta Lacks, ending litigation over the unauthorized use of her 'immortal' HeLa cells. This marks the latest in a series of legal victories for the Lacks family against pharmaceutical giants that profited from cells taken without consent in 1951.
This page surfaces every story mentioning Ben Crump across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Ben Crump was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |